

CONTENTS

INTRODUCTION	1
------------------------	---

Part I Experimental Study

1. EXPERIMENTAL MODELS	9
1.1 Introduction.	9
1.2 Cerebral Infarction Models	10
1.2.1 Experimental Models Using the Monkey	10
1.2.2 Experimental Models Using the Dog	11
1.2.3 Experimental Models Using the Cat	11
1.2.4 Experimental Models Using the Rat	12
1.2.5 Experimental Models Using the Gerbil	13
1.3 The Cerebral Infarction Model Developed in Sendai	13
1.3.1 Production of Various Cerebral Infarction Models in the Dog by Means of Occlusion of Intracranial Trunk Arteries.	13
1.3.1.1 Thalamic Infarction Model	13
1.3.1.2 Cerebral Mantle Infarction Model	15
1.3.1.3 Complete Cerebral Hemisphere Infarction Model	16
1.3.1.4 Incomplete Cerebral Hemisphere Infarction Model.	16
1.3.1.5 Complete Ischemic Brain Regulated with the Perfusion Method.	17
1.3.2 A 3-Vessel Occlusion Model for Bilateral Hemispheric Infarction Using the Rat	19
1.3.2.1 Production of the Ischemia-Model	19
1.3.2.2 EEG Studies	20
1.3.2.3 Studies of the Cerebral Blood Flow Using Autoradiography	20
2. HISTOLOGICAL STUDY	23
2.1 Introduction.	23
2.2 Sequential Changes in Cerebral Ischemia	25
2.2.1 Sequential Changes in Focal Ischemia	25

2.2.1.1	Acute Stage Changes in an Ischemic Focus	25
2.2.1.2	Changes in the Ischemic Focus Following Acute Stage Recirculation	31
2.2.1.3	Changes in Ischemic Foci During the Subacute and Chronic Stages	40
2.2.2	Sequential Changes in Global Ischemia	45
2.2.2.1	Observations Using the Light Microscope	46
2.2.2.2	Observations Using the Electron Microscope	46
2.2.2.3	Observation Using the Freeze Fracture Method	50
3.	CEREBRAL BLOOD FLOW	54
3.1	Introduction.	54
3.2	Correlation Between Regional EEG and rCBF	56
3.3	Regional Cerebral Hemodynamics Following Recirculation	58
3.3.1	Hemodynamics at the Center of an Ischemic Focus	58
3.3.2	Hemodynamics of the Border and Periphery of an Ischemic Focus	66
3.4	Sequential Changes in Vascular Reactivities	72
3.4.1	Autoregulation	72
3.4.1.1	Sequential Change in Autoregulation Occurring at the Center of an Ischemic Focus	73
3.4.1.2	Sequential Changes in Autoregulation at the Border and in the Periphery of an Ischemic Focus	76
3.4.2	CO ₂ Response	78
3.5	Hemorrhagic Infarction	84
3.5.1	Conditions Conductive to Hemorrhagic Infarction	84
3.5.2	Hemodynamics Following Recirculation.	85
4.	ISCHEMIC BRAIN EDEMA	89
4.1	Introduction.	89
4.1.1	The Definition of Ischemic Brain Edema	89
4.1.2	Pathophysiology of Ischemic Brain Edema	89
4.1.2.1	Causal Factors	89
4.1.2.2	The Onset and Natural Course of Ischemic Brain Edema	94
4.1.2.3	Ischemic Brain Edema Following Recirculation	96
4.1.2.4	The Disappearance of Edema.	97
4.1.3	The Treatment of Ischemic Brain Edema	99
4.1.3.1	General Therapeutic Steps.	99
4.1.3.2	Drug Therapy	99
5.	CEREBRAL METABOLISM AND FREE RADICAL PATHOLOGY	102
5.1	Introduction.	102
5.2	Phospholipids as Biomembrane Constituents.	104
5.3	Ca ²⁺ Homeostasis.	107

5.4	Lipid Metabolism in Cerebral Ischemia	108
5.5	The Free Radical Reaction in Cerebral Ischemia	112
5.5.1	Fundamental Knowledge Concerning Free Radicals.	113
5.5.2	Lipid Peroxidation	114
5.5.3	Detection of Free Radicals	116
5.5.3.1	Chemiluminescence	116
5.5.3.2	Electron Spin Resonance (ESR)	119
5.5.4	Initiators of Autoxidative Lipid Peroxidation	123
5.5.4.1	Superoxide Anion ($O_2^{\cdot-}$)	123
5.5.4.2	Hydroxy Radical ($OH^{\cdot}$)	124
5.5.4.3	Oxygen-Metal Complexes	124
5.5.4.4	Singlet Oxygen (1O_2)	125
5.5.5	Energy Metabolism and Free Radical Generation	126
5.5.6	The Problem of "Intra-Ischemic Peroxidation" and "Post-Ischemic Peroxidation"	134
5.6	Pharmacological Mechanisms of Mannitol, Vitamin E, Glucocorticoids and Phenytoin	138
5.6.1	Mannitol	138
5.6.2	Vitamin E (α -tocopherol)	141
5.6.3	Glucocorticoids	143
5.6.4	Combined Therapy with Mannitol, Vitamin E and Glucocorticoid	146
5.6.5	Phenytoin (Aleviatin)	153
6.	THE DEVELOPMENT OF NEW BRAIN PROTECTIVE AGENTS	158
6.1	Introduction.	158
6.2	Brain Protective Agents—Short Review	160
6.2.1	Barbiturates	160
6.2.2	Naloxone	164
6.2.3	Prostaglandins and Indomethacin	167
6.3	Development of a New Brain Protective Substance—Our Study	169
6.3.1	Mannitol	169
6.3.1.1	The Effect of Mannitol on Cerebral Ischemia— Histological Study	169
6.3.1.2	Recirculation in the Acute Period of Cerebral Infarction: Brain Swelling and Its Suppression Using Mannitol	170
6.3.1.3	The Effect of Mannitol on Cerebral Ischemia— CBF Study	175
6.3.2	Perfluorochemicals (PFC)	177
6.3.2.1	Introduction	177
6.3.2.2	PFC and Brain Tissue Partial Oxygen Pressure (PtO_2)	178

6.3.3	Combined Administration of Mannitol and PFC . . .	182
6.3.3.1	Recovery of Brain Electrical Activity in the Severely Ischemic Brain	182
6.3.3.2	Suppression of Hemorrhagic Infarction	184
6.3.4	The Protective Effects of Various Free Radical Scavengers	185
6.3.5	Combined Administration of Mannitol, Vitamin E, Dexamethasone and PFC	189
6.3.5.1	Experimental Results: Untreated Control Group (22 Dogs)	190
6.3.5.2	Drug-Treated Animals (61 Dogs)	192
6.3.6	Phenytoin (Aleviatin)	195
6.3.7	Calcium Antagonist (Flunarizine)	199

Part II

Clinical Study

7.	EPIDEMIOLOGY AND SYMPTOMATOLOGY	205
7.1	Introduction	205
7.2	The Natural Course of the Acute Stage of Cerebral Infarction: a Study of 1,000 Cases	208
7.2.1	Analysis of 1,000 Cases: Prognosis	211
7.2.1.1	Description of the 1,000 Cases	211
7.2.1.2	Lesion Site and Outcome	211
7.2.1.3	Age and Prognosis	213
7.2.1.4	Study of Fatalities	213
7.2.2	Occlusion of the Internal Carotid Artery	216
7.2.2.1	ICA Occlusion and Prognosis	216
7.2.2.2	Acute Stage Disturbances of Consciousness and Prognosis	218
7.2.2.3	Acute Stage Motor Deficits and Prognosis . . .	218
7.2.2.4	CT Findings in ICA Occlusion	219
7.2.2.5	Fatalities Among the ICA Cases	220
7.2.3	Occlusion of the Middle Cerebral Artery	221
7.2.3.1	MCA Occlusion and Prognosis	221
7.2.3.2	Acute Stage Disturbances of Consciousness and Prognosis	222
7.2.3.3	Acute Stage Motor Deficits and Prognosis . . .	224
7.2.4	Ischemic Cerebrovascular Disease Without Positive Angiographical Findings	226
7.2.4.1	Relationship to Prognosis	226
7.2.4.2	Acute Stage Neurological Deficits and Prognosis	228
7.2.4.3	CT Findings	228

8.	DIAGNOSTIC TECHNIQUES	231
8.1	Introduction.	231
8.2	Techniques for Obtaining Information Concerning the Cerebral Vessels	232
8.2.1	Cerebral Angiography Using the Direct Puncture and Seldinger's Methods	232
8.2.2	Digital Subtraction Angiography (DSA).	233
8.3	Techniques for Obtaining Morphological Information	236
8.3.1	X-ray Computerized Tomography (CT).	237
8.3.1.1	Low Density Areas	237
8.3.1.2	Mass Signs Due to Cerebral Edema	238
8.3.1.3	Cerebral Atrophy	239
8.3.1.4	Contrast Enhancement Effects	239
8.3.1.5	High Density Areas	241
8.3.2	Nuclear Magnetic Resonance Computed Tomography (NMR-CT)	242
8.4	Techniques for Obtaining Information Concerning Cerebral Blood Flow and Metabolism	246
8.4.1	Two-dimensional Measurement Techniques	247
8.4.2	Three-dimensional Measurement Techniques	247
8.4.2.1	Dynamic CT	248
8.4.2.2	The Stable Xenon-enhanced CT Technique.	248
8.4.2.3	Single Photon Emission CT Scanning (SPECT)	249
8.4.2.4	PET Scanning	249
8.4.3	The Pathophysiology of Cerebral Infarction as Seen from Measurements of Cerebral Blood Flow and Metabolism	250
9A.	MEDICAL TREATMENT OF CEREBRAL INFARCTION	252
9A.1	Introduction.	252
9A.2	Control of Blood Pressure	252
9A.2.1	Control of Blood Pressure in the Acute Stage	252
9A.2.2	Control of Blood Pressure in the Chronic Stage	253
9A.3	Treatment to Suppress Cerebral Edema	254
9A.3.1	Hypertonic Solutions	254
9A.3.2	Corticosteroids	255
9A.4	Antithrombotic Therapy	255
9A.4.1	Antiplatelet Agents	255
9A.4.2	Anticoagulants	256
9A.4.3	Thrombolytic Agents	256
9A.5	Facilitators of Cerebral Blood Flow	257
9A.5.1	Cerebral Vasodilators	257
9A.5.2	Low Molecular Weight Dextran (Dextran 40).	258
9A.5.3	Exsanguination	259
9A.6	Activators of Cerebral Metabolism	259

9A.7 Cerebral Protective Agents	259
9A.7.1 Barbiturate Therapy	259
9A.7.2 The Sendai Cocktail	261
9A.7.3 Other Drugs with Protective Effects on the Brain	261
9B. SURGICAL TREATMENT FOR CEREBRAL INFARCTION	262
9B.1 Introduction.	262
9B.2 Surgical Treatment for Occlusive Diseases of the Extracranial Carotid Arteries	262
9B.2.1 Internal Carotid Endarterectomy (ICEA)	262
9B.2.2 External Carotid Endarterectomy (ECEA)	265
9B.2.3 Stumpectomy.	265
9B.2.4 Tortuosity, Coiling and Kinking	265
9B.3 Surgical Therapy for Occlusive Lesions of the Extracranial Vertebral Artery	266
9B.4 Intracranial Vascular Reconstruction	267
9B.4.1 Vascular Reconstruction of the Anterior Circulation	267
9B.4.2 Vascular Reconstruction of the Posterior Circulation	268
9B.4.3 Vein Grafts	268
9C. REVASCULARIZATION IN ACUTE STAGE	270
9C.1 Introduction.	270
9C.2 Surgical Therapy in the Acute Stage of Major Stroke Cases	271
9C.3 Acute Stage Vascular Reconstruction Using the "Sendai Cocktail"—Our Series of Patients	272
9C.3.1 Treatment and Indication	272
9C.3.2 Materials	273
9C.3.3 Results	273
9C.3.3.1 Overall Results	273
9C.3.3.2 Results of Cases of Thrombosis and Embolism	273
9C.3.4 Conclusion.	276
9C.4 Acute Vascular Reconstruction for Progressing Stroke	277
9C.5 The Present Series of Progressing Stroke Cases.	278

Part III

Appendixes

10. TEMPORARY OCCLUSION OF TRUNK ARTERIES OF THE BRAIN DURING SURGERY	283
10.1 Introduction.	283
10.2 Decrease in Cerebral Blood Flow Due to Temporary Clipping and Countermeasures—the Development of Methods to Prolong the Safe Time Limit for Vascular Occlusion	284
10.3 Damage to the Vascular Wall Due to the Temporary Clip	289

11. THE PATHOLOGY OF CEREBRAL VASOSPASMS AND ITS TREATMENT	291
11.1 Introduction.	291
11.2 The Pathology of Cerebral Vasospasm	291
11.3 Mechanisms of Onset and Causal Factors of Vasospasm	296
11.4 Treatment of Cerebral Vasospasm	301
11.4.1 Drug Therapy	301
11.4.2 Surgical Treatment	305
11.4.3 Our Procedure for Prevention and Treatment	306
12. SURGICAL THERAPY FOR MOYAMOYA DISEASE	307
12.1 Introduction	307
12.2 The Characteristic Pathophysiology of Moyamoya Disease	308
12.3 Surgical Therapy for Ischemic Moyamoya Disease	310
12.3.1 Durapexia	310
12.3.2 Cervical Perivascular Sympathectomy and Superior Cervical Ganglionectomy	310
12.3.3 Superficial Temporal Artery-Cortical Branch of the Middle Cerebral Artery Anastomosis (STA-MCA Anastomosis) and Encephalo-myo-synangiosis (EMS)	310
12.3.4 Transplantation of Omentum	311
12.3.5 Encephalo-Duro-Arterio-Synangiosis (EDAS)	311
12.3.6 Other Techniques for Improving Cerebral Blood Flow	312
12.4 Our Own Therapeutic Technique: Cervical Perivascular Sympathectomy (PVS) and Superior Cervical Ganglionectomy (SCG)	312
12.4.1 The Surgical Method	313
12.4.2 Follow-up Clinical Symptoms	314
12.4.3 Angiographical Follow-up	316
12.4.4 Electroencephalographical Follow-up	319
12.4.5 The Effects of PVS and SCG, as Monitored During Surgery	320
12.5 Anesthesia, Pre- and Postoperative Management in Moyamoya Disease	321
12.5.1 Study of the “Re-build Up” Phenomenon Using EEG, Angiography and PET	321
12.5.2 Anesthesia, Pre- and Postoperative Management	324
References	326
Chapter 1	326
Chapter 2	328
Chapter 3	331
Chapter 4	333
Chapter 5	336
Chapter 6	347

XIV	Contents
Chapter 7	352
Chapter 8	353
Chapter 9A	355
Chapter 9B	357
Chapter 9C	360
Chapter 10	362
Chapter 11	363
Chapter 12	367
Subject Index.	371